How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
48
VNDA Quote, Financials, Valuation and Earnings
Last price:
$7.79
Seasonality move
:
-4.2%
Day range:
$7.67 - $8.09
52-week range:
$3.81 - $9.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.13x
P/B ratio:
0.98x
Volume:
941.4K
Avg. volume:
2.3M
1-year change:
73.2%
Market cap:
$454.5M
Revenue:
$198.8M
EPS (TTM):
-$1.43
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$59.3M | -- | 23.5% | -- | $13.63 |
|
ABBV
AbbVie, Inc.
|
$16.4B | $2.65 | 11.62% | 332.15% | $245.04 |
|
ALDX
Aldeyra Therapeutics, Inc.
|
$24.3M | -$0.15 | -- | -44.74% | $9.67 |
|
ANAB
AnaptysBio, Inc.
|
$87.1M | $0.93 | -26.24% | -13.94% | $67.92 |
|
AXSM
Axsome Therapeutics, Inc.
|
$191.3M | -$0.75 | 57.25% | -43.6% | $210.19 |
|
LLY
Eli Lilly & Co.
|
$18B | $6.95 | 35.51% | 147.92% | $1,133.93 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$7.69 | $13.63 | $454.5M | -- | $0.00 | 0% | 2.13x |
|
ABBV
AbbVie, Inc.
|
$218.67 | $245.04 | $386.5B | 165.00x | $1.73 | 3.04% | 6.49x |
|
ALDX
Aldeyra Therapeutics, Inc.
|
$5.42 | $9.67 | $326.1M | -- | $0.00 | 0% | -- |
|
ANAB
AnaptysBio, Inc.
|
$47.45 | $67.92 | $1.3B | -- | $0.00 | 0% | 8.32x |
|
AXSM
Axsome Therapeutics, Inc.
|
$185.17 | $210.19 | $9.3B | -- | $0.00 | 0% | 16.24x |
|
LLY
Eli Lilly & Co.
|
$1,023.80 | $1,133.93 | $916.3B | 50.63x | $1.50 | 0.59% | 15.71x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VNDA
Vanda Pharmaceuticals, Inc.
|
2.29% | -0.960 | 3.7% | 2.92x |
|
ABBV
AbbVie, Inc.
|
104% | -0.205 | 16.8% | 0.47x |
|
ALDX
Aldeyra Therapeutics, Inc.
|
23.99% | 2.161 | 4.95% | 2.64x |
|
ANAB
AnaptysBio, Inc.
|
109.28% | 0.355 | 41.03% | 8.52x |
|
AXSM
Axsome Therapeutics, Inc.
|
74.78% | -0.062 | 3.58% | 1.45x |
|
LLY
Eli Lilly & Co.
|
64.11% | -0.496 | 6.22% | 0.65x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$51.6M | -$31.3M | -16.2% | -16.55% | -55.61% | -$31.8M |
|
ABBV
AbbVie, Inc.
|
$10.4B | $4.6B | 3.31% | 144.3% | 29.03% | $6.6B |
|
ALDX
Aldeyra Therapeutics, Inc.
|
-$63.7K | -$8M | -53.75% | -66.61% | -- | -$7M |
|
ANAB
AnaptysBio, Inc.
|
$75.7M | $34.7M | -22.38% | -367.62% | 45.47% | -$27.4M |
|
AXSM
Axsome Therapeutics, Inc.
|
$156.7M | -$32.9M | -82.07% | -327.97% | -19.26% | $988K |
|
LLY
Eli Lilly & Co.
|
$14.6B | $8.4B | 33.81% | 106.26% | 47.65% | $6B |
Vanda Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns VNDA or ABBV?
AbbVie, Inc. has a net margin of -40.15% compared to Vanda Pharmaceuticals, Inc.'s net margin of 1.13%. Vanda Pharmaceuticals, Inc.'s return on equity of -16.55% beat AbbVie, Inc.'s return on equity of 144.3%.
Company Gross Margin Earnings Per Share Invested Capital VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M ABBVAbbVie, Inc.66.12% $0.10 $66.1B -
What do Analysts Say About VNDA or ABBV?
Vanda Pharmaceuticals, Inc. has a consensus price target of $13.63, signalling upside risk potential of 77.18%. On the other hand AbbVie, Inc. has an analysts' consensus of $245.04 which suggests that it could grow by 12.06%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than AbbVie, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than AbbVie, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VNDAVanda Pharmaceuticals, Inc.3 1 0 ABBVAbbVie, Inc.13 9 0 -
Is VNDA or ABBV More Risky?
Vanda Pharmaceuticals, Inc. has a beta of 0.604, which suggesting that the stock is 39.647% less volatile than S&P 500. In comparison AbbVie, Inc. has a beta of 0.359, suggesting its less volatile than the S&P 500 by 64.064%.
-
Which is a Better Dividend Stock VNDA or ABBV?
Vanda Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AbbVie, Inc. offers a yield of 3.04% to investors and pays a quarterly dividend of $1.73 per share. Vanda Pharmaceuticals, Inc. pays -- of its earnings as a dividend. AbbVie, Inc. pays out 263.15% of its earnings as a dividend.
-
Which has Better Financial Ratios VNDA or ABBV?
Vanda Pharmaceuticals, Inc. quarterly revenues are $56.3M, which are smaller than AbbVie, Inc. quarterly revenues of $15.8B. Vanda Pharmaceuticals, Inc.'s net income of -$22.6M is lower than AbbVie, Inc.'s net income of $178M. Notably, Vanda Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while AbbVie, Inc.'s PE ratio is 165.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals, Inc. is 2.13x versus 6.49x for AbbVie, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VNDAVanda Pharmaceuticals, Inc.2.13x -- $56.3M -$22.6M ABBVAbbVie, Inc.6.49x 165.00x $15.8B $178M
-
Which has Higher Returns VNDA or ALDX?
Aldeyra Therapeutics, Inc. has a net margin of -40.15% compared to Vanda Pharmaceuticals, Inc.'s net margin of --. Vanda Pharmaceuticals, Inc.'s return on equity of -16.55% beat Aldeyra Therapeutics, Inc.'s return on equity of -66.61%.
Company Gross Margin Earnings Per Share Invested Capital VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M -
What do Analysts Say About VNDA or ALDX?
Vanda Pharmaceuticals, Inc. has a consensus price target of $13.63, signalling upside risk potential of 77.18%. On the other hand Aldeyra Therapeutics, Inc. has an analysts' consensus of $9.67 which suggests that it could grow by 78.35%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than Vanda Pharmaceuticals, Inc., analysts believe Aldeyra Therapeutics, Inc. is more attractive than Vanda Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VNDAVanda Pharmaceuticals, Inc.3 1 0 ALDXAldeyra Therapeutics, Inc.4 0 0 -
Is VNDA or ALDX More Risky?
Vanda Pharmaceuticals, Inc. has a beta of 0.604, which suggesting that the stock is 39.647% less volatile than S&P 500. In comparison Aldeyra Therapeutics, Inc. has a beta of 0.858, suggesting its less volatile than the S&P 500 by 14.241%.
-
Which is a Better Dividend Stock VNDA or ALDX?
Vanda Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aldeyra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Aldeyra Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VNDA or ALDX?
Vanda Pharmaceuticals, Inc. quarterly revenues are $56.3M, which are larger than Aldeyra Therapeutics, Inc. quarterly revenues of --. Vanda Pharmaceuticals, Inc.'s net income of -$22.6M is lower than Aldeyra Therapeutics, Inc.'s net income of -$7.7M. Notably, Vanda Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Aldeyra Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals, Inc. is 2.13x versus -- for Aldeyra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VNDAVanda Pharmaceuticals, Inc.2.13x -- $56.3M -$22.6M ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M
-
Which has Higher Returns VNDA or ANAB?
AnaptysBio, Inc. has a net margin of -40.15% compared to Vanda Pharmaceuticals, Inc.'s net margin of 19.8%. Vanda Pharmaceuticals, Inc.'s return on equity of -16.55% beat AnaptysBio, Inc.'s return on equity of -367.62%.
Company Gross Margin Earnings Per Share Invested Capital VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M ANABAnaptysBio, Inc.99.2% $0.52 $317M -
What do Analysts Say About VNDA or ANAB?
Vanda Pharmaceuticals, Inc. has a consensus price target of $13.63, signalling upside risk potential of 77.18%. On the other hand AnaptysBio, Inc. has an analysts' consensus of $67.92 which suggests that it could grow by 43.13%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than AnaptysBio, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than AnaptysBio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VNDAVanda Pharmaceuticals, Inc.3 1 0 ANABAnaptysBio, Inc.9 1 0 -
Is VNDA or ANAB More Risky?
Vanda Pharmaceuticals, Inc. has a beta of 0.604, which suggesting that the stock is 39.647% less volatile than S&P 500. In comparison AnaptysBio, Inc. has a beta of 0.317, suggesting its less volatile than the S&P 500 by 68.3%.
-
Which is a Better Dividend Stock VNDA or ANAB?
Vanda Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AnaptysBio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals, Inc. pays -- of its earnings as a dividend. AnaptysBio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VNDA or ANAB?
Vanda Pharmaceuticals, Inc. quarterly revenues are $56.3M, which are smaller than AnaptysBio, Inc. quarterly revenues of $76.3M. Vanda Pharmaceuticals, Inc.'s net income of -$22.6M is lower than AnaptysBio, Inc.'s net income of $15.1M. Notably, Vanda Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while AnaptysBio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals, Inc. is 2.13x versus 8.32x for AnaptysBio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VNDAVanda Pharmaceuticals, Inc.2.13x -- $56.3M -$22.6M ANABAnaptysBio, Inc.8.32x -- $76.3M $15.1M
-
Which has Higher Returns VNDA or AXSM?
Axsome Therapeutics, Inc. has a net margin of -40.15% compared to Vanda Pharmaceuticals, Inc.'s net margin of -27.62%. Vanda Pharmaceuticals, Inc.'s return on equity of -16.55% beat Axsome Therapeutics, Inc.'s return on equity of -327.97%.
Company Gross Margin Earnings Per Share Invested Capital VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M AXSMAxsome Therapeutics, Inc.91.62% -$0.94 $292.3M -
What do Analysts Say About VNDA or AXSM?
Vanda Pharmaceuticals, Inc. has a consensus price target of $13.63, signalling upside risk potential of 77.18%. On the other hand Axsome Therapeutics, Inc. has an analysts' consensus of $210.19 which suggests that it could grow by 13.51%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Axsome Therapeutics, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Axsome Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VNDAVanda Pharmaceuticals, Inc.3 1 0 AXSMAxsome Therapeutics, Inc.16 1 0 -
Is VNDA or AXSM More Risky?
Vanda Pharmaceuticals, Inc. has a beta of 0.604, which suggesting that the stock is 39.647% less volatile than S&P 500. In comparison Axsome Therapeutics, Inc. has a beta of 0.438, suggesting its less volatile than the S&P 500 by 56.163%.
-
Which is a Better Dividend Stock VNDA or AXSM?
Vanda Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Axsome Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VNDA or AXSM?
Vanda Pharmaceuticals, Inc. quarterly revenues are $56.3M, which are smaller than Axsome Therapeutics, Inc. quarterly revenues of $171M. Vanda Pharmaceuticals, Inc.'s net income of -$22.6M is higher than Axsome Therapeutics, Inc.'s net income of -$47.2M. Notably, Vanda Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Axsome Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals, Inc. is 2.13x versus 16.24x for Axsome Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VNDAVanda Pharmaceuticals, Inc.2.13x -- $56.3M -$22.6M AXSMAxsome Therapeutics, Inc.16.24x -- $171M -$47.2M
-
Which has Higher Returns VNDA or LLY?
Eli Lilly & Co. has a net margin of -40.15% compared to Vanda Pharmaceuticals, Inc.'s net margin of 31.72%. Vanda Pharmaceuticals, Inc.'s return on equity of -16.55% beat Eli Lilly & Co.'s return on equity of 106.26%.
Company Gross Margin Earnings Per Share Invested Capital VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M LLYEli Lilly & Co.82.91% $6.21 $66.4B -
What do Analysts Say About VNDA or LLY?
Vanda Pharmaceuticals, Inc. has a consensus price target of $13.63, signalling upside risk potential of 77.18%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,133.93 which suggests that it could grow by 10.76%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..
Company Buy Ratings Hold Ratings Sell Ratings VNDAVanda Pharmaceuticals, Inc.3 1 0 LLYEli Lilly & Co.18 7 0 -
Is VNDA or LLY More Risky?
Vanda Pharmaceuticals, Inc. has a beta of 0.604, which suggesting that the stock is 39.647% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.
-
Which is a Better Dividend Stock VNDA or LLY?
Vanda Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.50 per share. Vanda Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios VNDA or LLY?
Vanda Pharmaceuticals, Inc. quarterly revenues are $56.3M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Vanda Pharmaceuticals, Inc.'s net income of -$22.6M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Vanda Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 50.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals, Inc. is 2.13x versus 15.71x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VNDAVanda Pharmaceuticals, Inc.2.13x -- $56.3M -$22.6M LLYEli Lilly & Co.15.71x 50.63x $17.6B $5.6B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
72
BNAI alert for Jan 29
Brand Engagement Network, Inc. [BNAI] is down 16.89% over the past day.
Buy
82
STX alert for Jan 29
Seagate Technology Holdings Plc [STX] is up 0.83% over the past day.
Buy
84
GDXU alert for Jan 29
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 12.19% over the past day.
